Dyax Corp. Announces First Market Approval from Licensing and Funded Research Program
Peptide ligand used in purification process during manufacture of Wyeth's XYNTHA
03-Mar-2008
Under the terms of the license agreement with Wyeth, Dyax is entitled to a milestone payment triggered by the first commercial sale of XYNTHA followed by royalties based on certain pre-determined sales levels.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.